Compare Altria Group Inc (MO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Tango Therapeutics Inc. — how do they compare? Altria Group Inc trades at $73.54 (market cap $119.49B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Altria Group Inc is far larger — about 31.9× Tango Therapeutics Inc.'s market cap, and Altria Group Inc pays a 6.2% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 155 Days and Tango Therapeutics Inc. for 0 Days on average.
| MO | TNGX | |
|---|---|---|
Market Cap | $119.49B | $3.75B |
Volume | 6,945,035 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $32.90 |
52-Week Low | $54.72 | $7.50 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $141.70B | $2.77B |
Dividend Yield | 6.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $73.16, up 2.09% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 39% net income margin and generates robust operating cash flow of $9.3B. Recent earnings show alternating beats and misses, while analyst consensus remains positive with 61.5% buy ratings despite negative shareholder equity of -$2.24B.
MO offers a high dividend yield but faces structural challenges including declining cigarette volumes and regulatory uncertainty. The stock trades below analyst consensus target of $69.71, suggesting limited upside. Key risks include negative equity, margin compression, and dependence on declining tobacco products despite smoke-free initiatives.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
